Genocea Biosciences (NASDAQ:GNCAQ) & Vericel (NASDAQ:VCEL) Head to Head Contrast

Vericel (NASDAQ:VCEL) and Genocea Biosciences (NASDAQ:GNCAQ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Earnings and Valuation

This table compares Vericel and Genocea Biosciences’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$197.52 million	11.53	-$3.18 million	($0.09)	-523.05
Genocea Biosciences	$1.64 million	N/A	-$33.20 million	N/A	N/A

Vericel has higher revenue and earnings than Genocea Biosciences.

Risk & Volatility

Vericel has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.31, meaning that its share price is 131% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Vericel and Genocea Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0	0	6	0	3.00
Genocea Biosciences	0	0	0	0	N/A

Vericel presently has a consensus price target of $46.40, indicating a potential downside of 1.44%.

Profitability

This table compares Vericel and Genocea Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vericel	-1.61%	-1.55%	-1.02%
Genocea Biosciences	N/A	N/A	N/A

Summary

Genocea Biosciences beats Vericel on 4 of the 7 factors compared between the two stocks.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.